FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3160975504> ?p ?o ?g. }

• W3160975504 abstract "<b><i>Purpose:</i></b> We aim to determine the effects of intravitreal aflibercept (IVA) on the mean sensitivity (MS) of the central retina, best-corrected visual acuity (BCVA), and central foveal thickness (CFT) in eyes with neovascular age-related macular degeneration (nAMD) with or without polypoidal choroidal vasculopathy (PCV). <b><i>Methods:</i></b> This was a prospective, interventional study. All eyes were treatment-naive with nAMD with or without PCV. Each eye received 3 monthly IVA injections followed by an IVA injection every 2 months for 12 months. The primary outcome was the change in the MS within the central 2°. The secondary outcomes were the changes in BCVA, CFT, greatest linear dimension (GLD), and percentage of eyes with a dry macula. <b><i>Results:</i></b> Thirty-seven eyes of 37 patients were studied. A significant improvement of the MS (dB) was observed +4.9 ± 4.6 dB (mean ± standard deviation) at 3 M (<i>p</i> &#x3c; 0.001), +5.5 ± 4.9 dB at 6 (<i>p</i> &#x3c; 0.001), and +7.0 ± 3.4 dB at 12 M (<i>p</i> &#x3c; 0.001) compared to the baseline in all eyes. The MS of the eyes with non-PCV was not significantly different from that of eyes with PCV (<i>p</i> = 1.00, 1.00, 1.00, and 0.76 at baseline, 3, 6, and 12 M, respectively). The MS of 11 patients whose BCVA remained unchanged was significantly improved by +6.5 ± 2.8 dB at 3 M (<i>p</i> &#x3c; 0.001), +6.1 ± 4.3 dB at 6 M (<i>p</i> &#x3c; 0.001), and +6.4 ± 4.8 dB at 12 M (<i>p</i> = 0.003) compared to the baseline. The mean BCVA was significantly improved from the baseline to 3 M (<i>p</i> &#x3c; 0.001), 6 M (<i>p</i> = 0.027), and 12 M (<i>p</i> = 0.003) in all eyes. The BCVA was improved or maintained in 97% of the patients at 12 M. The mean CFT and GLD were significantly reduced at 12 M (<i>p</i> &#x3c; 0.001). Twenty-two eyes (71%) had a dry macula at 12 M. <b><i>Conclusions:</i></b> IVA administered by a fixed dosing regimen led to significant improvements of the central MS, BCVA, and macular morphology at 1 year in eyes with nAMD with or without PCV. These results were not significantly different between eyes with non-PCV and with PCV. The improvements of the MS of the retina of the central 2° in a subgroup whose BCVA remained unchanged through the 12-month experimental period was also significant. We conclude that the MS of the central 2° might be a better marker than the BCVA in determining the effectiveness of IVA treatments and might be helpful in determining early effects on the retina before BCVA changes can be detected." @default.
• W3160975504 created "2021-05-24" @default.
• W3160975504 creator A5018426062 @default.
• W3160975504 creator A5023903414 @default.
• W3160975504 creator A5025031468 @default.
• W3160975504 creator A5027211308 @default.
• W3160975504 creator A5028820608 @default.
• W3160975504 creator A5035670774 @default.
• W3160975504 creator A5043299357 @default.
• W3160975504 creator A5044028945 @default.
• W3160975504 creator A5044310971 @default.
• W3160975504 creator A5056921813 @default.
• W3160975504 creator A5059011724 @default.
• W3160975504 creator A5074115820 @default.
• W3160975504 creator A5076061569 @default.
• W3160975504 date "2021-01-01" @default.
• W3160975504 modified "2023-10-17" @default.
• W3160975504 title "Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy" @default.
• W3160975504 cites W1975251395 @default.
• W3160975504 cites W1983920824 @default.
• W3160975504 cites W1992670872 @default.
• W3160975504 cites W2004117352 @default.
• W3160975504 cites W2013349518 @default.
• W3160975504 cites W2020482183 @default.
• W3160975504 cites W2029023024 @default.
• W3160975504 cites W2038212680 @default.
• W3160975504 cites W2041610458 @default.
• W3160975504 cites W2055822421 @default.
• W3160975504 cites W2068742492 @default.
• W3160975504 cites W2081233482 @default.
• W3160975504 cites W2093044616 @default.
• W3160975504 cites W2093910597 @default.
• W3160975504 cites W2095267692 @default.
• W3160975504 cites W2115397478 @default.
• W3160975504 cites W2124415048 @default.
• W3160975504 cites W2134161293 @default.
• W3160975504 cites W2143874967 @default.
• W3160975504 cites W2170979873 @default.
• W3160975504 cites W2299415664 @default.
• W3160975504 cites W2412434883 @default.
• W3160975504 cites W2469892467 @default.
• W3160975504 cites W2586417933 @default.
• W3160975504 cites W2887138320 @default.
• W3160975504 cites W2912131519 @default.
• W3160975504 cites W2914844160 @default.
• W3160975504 cites W2919727724 @default.
• W3160975504 cites W2987522660 @default.
• W3160975504 cites W2989380161 @default.
• W3160975504 cites W3091122622 @default.
• W3160975504 cites W2618073467 @default.
• W3160975504 doi "https://doi.org/10.1159/000517187" @default.
• W3160975504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34015785" @default.
• W3160975504 hasPublicationYear "2021" @default.
• W3160975504 type Work @default.
• W3160975504 sameAs 3160975504 @default.
• W3160975504 citedByCount "0" @default.
• W3160975504 crossrefType "journal-article" @default.
• W3160975504 hasAuthorship W3160975504A5018426062 @default.
• W3160975504 hasAuthorship W3160975504A5023903414 @default.
• W3160975504 hasAuthorship W3160975504A5025031468 @default.
• W3160975504 hasAuthorship W3160975504A5027211308 @default.
• W3160975504 hasAuthorship W3160975504A5028820608 @default.
• W3160975504 hasAuthorship W3160975504A5035670774 @default.
• W3160975504 hasAuthorship W3160975504A5043299357 @default.
• W3160975504 hasAuthorship W3160975504A5044028945 @default.
• W3160975504 hasAuthorship W3160975504A5044310971 @default.
• W3160975504 hasAuthorship W3160975504A5056921813 @default.
• W3160975504 hasAuthorship W3160975504A5059011724 @default.
• W3160975504 hasAuthorship W3160975504A5074115820 @default.
• W3160975504 hasAuthorship W3160975504A5076061569 @default.
• W3160975504 hasConcept C118487528 @default.
• W3160975504 hasConcept C141071460 @default.
• W3160975504 hasConcept C2776403814 @default.
• W3160975504 hasConcept C2776694085 @default.
• W3160975504 hasConcept C2777802072 @default.
• W3160975504 hasConcept C2778257484 @default.
• W3160975504 hasConcept C2778749236 @default.
• W3160975504 hasConcept C2780827179 @default.
• W3160975504 hasConcept C2781100027 @default.
• W3160975504 hasConcept C2781359195 @default.
• W3160975504 hasConcept C71924100 @default.
• W3160975504 hasConceptScore W3160975504C118487528 @default.
• W3160975504 hasConceptScore W3160975504C141071460 @default.
• W3160975504 hasConceptScore W3160975504C2776403814 @default.
• W3160975504 hasConceptScore W3160975504C2776694085 @default.
• W3160975504 hasConceptScore W3160975504C2777802072 @default.
• W3160975504 hasConceptScore W3160975504C2778257484 @default.
• W3160975504 hasConceptScore W3160975504C2778749236 @default.
• W3160975504 hasConceptScore W3160975504C2780827179 @default.
• W3160975504 hasConceptScore W3160975504C2781100027 @default.
• W3160975504 hasConceptScore W3160975504C2781359195 @default.
• W3160975504 hasConceptScore W3160975504C71924100 @default.
• W3160975504 hasLocation W31609755041 @default.
• W3160975504 hasOpenAccess W3160975504 @default.
• W3160975504 hasPrimaryLocation W31609755041 @default.
• W3160975504 hasRelatedWork W10664570 @default.
• W3160975504 hasRelatedWork W15010885 @default.
• W3160975504 hasRelatedWork W18974747 @default.
• W3160975504 hasRelatedWork W19022978 @default.
• W3160975504 hasRelatedWork W3599615 @default.

• next